CytoReason, an Israeli machine learning company, has announced that it has entered into a collaboration agreement with Pfizer. Under the terms of the agreement, Pfizer will use CytoReason's technology to develop immune system cell-based models.

The platform developed by sarcoidosis market organize, and incorporate Pfizer's data into an immune system model that will better explain how cells respond to a disease.

Machine learning models and algorithms can learn and improve when they have access to data. This makes it easier to find new drug targets, biomarkers, and indications that a drug could treat.

In accordance with the terms of the agreement, CytoReason will receive from Pfizer success-based payments, research support, and access fees totaling in the low to mid-dozen million US dollars.

Michael Vincent, chief scientific officer of inflammation and immunology at Pfizer, stated: We believe that CytoReason's platform has the potential to provide useful information that could be used in our study of the immune system in humans.

"Using technologies like this can help us understand disease, prioritize targets, and support our mission of delivering novel new therapies to patients who need them,"

For more insights on the sarcoidosis market, Download a Free Sample

The simulation models developed by CytoReason function by reassembling lost cellular data from gene expression data, tying genes to specific cells, and integrating this data with omics and literature data.

David Harel, the CEO and co-founder of the Israeli business, stated: Our models in our core therapeutic areas will be strengthened further through the collaboration with Pfizer. This will be our fifth major partnership, and we believe it will contribute to making our model's accuracy for pipeline assets unparalleled.

"CytoReason's model brings together thousands of samples at the cell-protein-gene level, making it possible to gain quick and accurate insights."

Since its establishment in 2016, CytoReason has collaborated with ten organizations from both the public and private sectors.

The company has collaborated with the Faculty of Medicine at the Technion-Israel Institute of Technology on four therapeutic discoveries, including cellular players in the melanoma microenvironment and pre-treatment biomarkers in inflammatory bowel disease.